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Purpose: Reliable biological markers for patients with the autoimmune neuromuscular disorder myasthenia
gravis (MG) are lacking. We determined whether levels of the circulating immuno-microRNAs miR-150-5p
andmiR-21-5pwere elevated in sera from clinically heterogeneousMG patients, with andwithout immunosup-
pression, as compared to healthy controls and patients with other autoimmune disorders.
Methods: Sera from 71MGpatients and 55 healthy controls (HC)were analyzed for the expression levels of miR-
150-5p andmiR-21-5pwith qRT-PCR. Serawere also assayed from23 patients with other autoimmune disorders
(AID; psoriasis, Addison's and Crohn's diseases).
Results: 34 MG patients had no immunosuppressive drug treatment (MG-0) and 37 patients were under stable
immunosuppressive drug treatment since ≥6 months (MG + IMM). Serum levels of miR-150-5p and miR-21-
5p were higher in the MG-0 patients compared to HC (p b 0.0001). Further, miR-150-5p levels were 41%
lower and miR-21-5p levels were 25% lower in the MG + IMM compared to MG-0 (p = 0.0051 and 0.0419).
In the AID patients, mean miR-150-5p and miR-21-5p were comparable with healthy controls (p = 0.66).
Conclusions: The immuno-microRNAs miR-150-5p and miR-21-5p show a disease speciﬁc signature, which sug-
gests these microRNAs as possible biological autoimmune markers of MG.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular
disorder, where the presence of MG speciﬁc autoantibodies, most
often the nicotinic acetylcholine receptors (AChR+) is important in
the diagnostic procedure. Autoantibody types in MG are to some extent
relevant not only diagnostically, since patients with antibodies against
muscle speciﬁc tyrosine kinase (MUSK) seem to have a different clinical
presentation and response to thymectomy compared to AChR+ MG.
Nevertheless, the autoantibody titer does not necessarily predict the
course of disease or the therapeutic response [1]. Due to the absence
of reliable biological markers for MG patients in clinical trials, recent
recommendations for clinical research standards imply the importance
of developing easily accessible parameters that support mechanistic
studies in clinical trials of pharmacotherapies [2,3].
Mammalian microRNAs (miRNAs) inhibit gene expression by
degrading or blocking translation of their target messenger RNAs
(mRNAs) [4] and thereby regulating gene expression pattern in variousnce, Clinical Neurophysiology,
Punga).
. This is an open access article underessential cellular processes [5]. Certain miRNAs are regarded as critical
factors in controlling the immune response and altered miRNA expres-
sion is related to various autoimmune diseases, including systemic
lupus erythematosus, rheumatoid arthritis and multiple sclerosis [6–8].
Moreover, miRNAs can circulate in the bloodstream in a stable, extracel-
lular form. Detection of circulating miRNAs can be used to follow various
disease states and therefore circulating miRNAs have been regarded as
potential blood-based biological markers [9]. In a recent report levels of
3 miRNAs (miR-150-5p, miR-21-5p and miR-27a-3p) were deregulated
in serum samples in a cohort of AChR+ female MG patients, of which
miR-150-5p was the most sensitive marker [10]. Regulatory T cells
(Tregs) control the autoimmune response and prevent autoimmunity.
Although normal in number, thymic Tregs display functional impairment
inMG patients [11]. Intriguingly, miR-150-5p has been speciﬁcally impli-
cated in the process of T cell maturation [12,13]; hence this miRNA could
provide a link to the autoimmune dysfunction in MG.
The aim of the present study was to validate whether circulating
miR-150-5p and miR-21-5p speciﬁcally accumulate in the sera of a
large heterogeneous cohort of male and female MG patients compared
to healthy controls (HC) and patientswith other autoimmunedisorders.
We also assessedwhether circulatingmiR-150-5p andmiR-21-5p levels
would be reduced in sera from MG patients with immunosuppressivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suppressants (MG-0), and thus if circulatingmiRNA levels would be re-
sponsive to immunomodulation.
2. Methods
2.1. Hypothesis and power calculation
The primary objective consisted of testing two separate hypotheses,
both based on mean miR-150-5p outcome: MG-0 = HC and MG-0 =
MG + IMM. Based on an assumed mean value for both HC and MG-
IMM of 60% of the mean for the MG-0 group and with a common stan-
dard deviation of 48% ofmeanMG-0 (based on previous data from [10])
it was calculated that at least 31 patients per group would be needed in
order to have 90% power to reject each hypothesis at 5% level.
As secondary exploratory objectives, we wanted to investigate a re-
lation between miR-150-5p and disease severity and whether there is
an increase of miR-150-5p in patients with other autoimmune disor-
ders. We also wanted to explore whether miR-21-5p is still elevated
and miR-27a-3p is decreased in a heterogeneous MG cohort.
2.2. Study group and clinical scoring
Blood samples were collected from 55 consecutive healthy blood
donors (28 females, mean age: 45 ± 16 years) at Uppsala University
Hospital. 71 MG patients (40 females; mean age: 57 ± 15 years),
who were referred to or regularly treated at the Neurology Clinic at
Uppsala University Hospital, were sampled for sera and assessed
clinically with the myasthenia gravis composite (MGC) score [14,
15]. A diagnosis of MG had been established according to the diag-
nostic criteria of the Myasthenia Gravis Foundation of America
(MGFA) [16] including objectivemuscle fatigue and neurophysiolog-
ical evidence of disturbed neuromuscular transmission (decrement
on repetitive nerve stimulation and/or increased jitter on single
ﬁber EMG), further supported by detection of AChR antibodies.
Each patient was given a total MGC score ranging from 0 (no myas-
thenic weakness) to maximum 50 points (worse possible myasthen-
ic weakness in all examined muscles). Patients with antibodies
against MuSK or Lrp4 were not included in this cohort due to differ-
ent IgG subtypes and clinical presentation in patients with these an-
tibodies. However, patients who were seronegative against AChR,
MuSK and Lrp4 were included if they fulﬁlled all other diagnostic
MG criteria.
Myasthenia Gravis Foundation of America (MGFA) disease sever-
ity grade was also assessed. The Swedish version of the health relat-
ed MG quality of life form (MGQ) [17], was applied to a subgroup of
35 patients. As the healthy control group, blood samples were col-
lected from 55 consecutive healthy blood donors (28 females,
mean age: 45 ± 16 years) without any medications. As the autoim-
mune control group, sera were inquired from 23 patients with
other autoimmune disorders (AID): Addison's disease (N = 8),
Crohn's disease (N = 11) and psoriasis (N = 4), (10 females; mean
age: 42.5 ± 14 years). The patients with Addison's disease were
substituted with b30 mg hydrocortisone (equivalent to 7.5 mg pred-
nisone), whereas the patients with psoriasis had only topical treat-
ment with corticosteroids and for the patients with Crohn's disease
no information regarding immunosuppressive treatment was avail-
able at the time of serum sampling.
The studywas approved by the local Ethical Review Board in Uppsa-
la (Dnr 2010/446) and all patients signed informed consent.
2.3. Circulating miRNA isolation and miRNA expression analysis
Blood samples were collected in tubes without any additives and
centrifuged, after at least 20 minute storage in room temperature, at
4000 rpm and 20 °C for 5 min. The serum samples were subsequentlystored at−80 °C until further processing. Total RNA was isolated from
200 μl serum by using miRCURY™ RNA Isolation Kit—Bioﬂuids (Exiqon
#300112), according to the manufacturer's instructions. 2 μl of isolated
RNA sample was applied for cDNA synthesis in a 10 μl reaction mix by
using Universal cDNA Synthesis Kit II (Exiqon #203301). The RT-qPCR
analysis was performed by using ExiLENT SYBR® Green master mix
(Exiqon #203421) on custom made Pick-&-Mix microRNA PCR panel
plates (Exiqon #203818) pre-coated with validated primer sets to am-
plify target miRNAs. The cDNA reactions were diluted 100× in ExiLENT
SYBR® Green master mix before applying to the Pick-&-Mix microRNA
PCR panel plates. All RT-qPCR reactions were carried out on 384-well
plates as described previously [10]. The following quality controls
were included on Pick-&-Mix microRNA PCR panel plates: the inter-
plate calibration (UniSp3), RNA extraction control (UniSp2 and
UniSp4), cDNA synthesis control (UniSp6) and hemolysis test (miR-
23a-3p–miR-451a) (Exiqon). The ΔCT value of hemolysis markers
(ΔCT(hemolysis) = CT(miR-23a-3p)− CT(miR-451a)), was used to detect he-
molysis. A ΔCT N 7 in serum samples indicates a high risk of hemolysis
and therefore these samples were not used for further analysis. Refer-
ence miRNAs, miR-93-5p, miR-191-5p, miR-423-4p and miR-103a,
were chosen since they have proven to have a stable expression both
in healthy controls and in MG patients [10]. Quantiﬁcation of relative
miRNA expression was performed with the comparative CT method
using the formula 2^−ΔΔCT, whereΔCT= [(CT gene of interest− CT ref-
erence gene) sample A − (CT gene of interest − CT reference gene)
sample B] by using the mean value of miR-93-5p, miR-191-5p, miR-
423-5p and miR-103a as the reference [10,18,19].
2.4. Statistical analysis
The study was designed as a case–control study. Log conversion of
the miRNA expression data was done in order to obtain data more sim-
ilar to a normal distribution for the statistical tests. To preserve the type
I error at 5%, the two statistical tests for the primary objective were per-
formed sequentiallywithMG-0 initially being compared to HC and only
if signiﬁcant could MG-0 and MG + IMM be compared without risk of
error inﬂation. No type I error control was applied for any of the other
statistical comparisons. All tests between disease groups (MG-0,
MG + IMM, HC, AID) were performed using a two-sample t-test with
a null hypothesis of equal means. In order to evaluate the relation be-
tween levels of categorical background factors (gender, MGFA class,
etc.) andmiR-150-5p, ANCOVAmodelswere used that included the dis-
ease group as an additional factor. Spearman rank correlation was per-
formed in order to determine the correlation coefﬁcient between
continuous factors (disease duration, age, etc.) and miR-150-5p. Statis-
tical signiﬁcance was deﬁned as a two-sided p b 0.05.
3. Results
3.1. Clinical characteristics of MG patients
We aimed at correlating clinical status of the MG patients with
serum levels of miRNA; thus patients were characterized by the clinical
group according to the MGFA class as well as the MG composite (MGC)
and quality of life score (MGQ), which reﬂects both objective and sub-
jective myasthenic symptoms. Further, patients were subdivided ac-
cording to their treatment with immunosuppression. 71 MG patients
were included in the study, out ofwhich34did not have any current im-
munosuppressive drug treatment for at least 6 months (25 females;
MG-0). 20 patients (59%) in this group were thymectomized and post
thymectomy time ranged from 4 to 36 years (Table 1). Out of these pa-
tients, 20 (59%) were on acetylcholinesterase inhibitors (AChEIs), rang-
ing from 60 to 720 mg daily, and the remaining patients did not have
any medication at all. 37 MG patients were treated with immunosup-
pressive agents at a stable dose for at least 6 months (MG+ IMM). Ex-
cept for treatmentwith corticosteroids and/or azathioprine, one patient
Table 1
Descriptive summary of current age and age at MG onset (years), number of female and
male patients and disease duration (years). MGC, Myasthenia Gravis Composite score.
Treatment characteristics for the different cohorts, Cort, corticosteroids; Aza, azathioprine;
Other immunosuppr: takrolimus, mycophenolate mofetil or sendoxan; Ab, antibody;
AChR+, acetylcholine receptor antibody seropositive; Seronegative; no detectable serum
antibodies against AChR, MuSK or Lrp4.
MG subgroup
MG-0 (N = 34) MG + IMM (N = 37)
Age (mean ± SD) 55 ± 15 59 ± 15
Age at MG onset (mean ± SD) 36 ± 19 49 ± 19
Gender
Female (N) 25 15
Male (N) 9 22
Disease duration
Mean ± SD (range)
18.5 ± 17.4
(0.3–57)
8.5 ± 9.6
(0.5–32)
MGC (mean ± SD) 6.1 ± 6.4 4.6 ± 6.1
Treatment N (%)
Only AChEIs 20 (59%)
No treatment 14 (41%)
Cort 21 (57%)
Aza 5 (13.5%)
Cort+ Aza 8 (21.5%)
Other immunosuppr 3 (8%)
Ab subtype N (%)
AChR+ 26 (76%) 26 (70%)
Seronegative 8 (24%) 11 (30%)
Thymectomy N (%) 20 (59%) 18 (49%)
Hyperplasia 11 (55%) 6 (33.5%)
Normal 8 (40%) 8 (44.5%)
Thymoma 1 (5%) 4 (22%)
92 A.R. Punga et al. / Journal of the Neurological Sciences 356 (2015) 90–96had sendoxane, one patient had only tacrolimus and one patient had
mycophenolate (Table 1). 18 (49%) patients in the MG + IMM group
had undergone thymectomy and post thymectomy time ranged from
2 to 28 years (Table 1). MGFA class ranged from class 1 (ocular MG)
to 4B (severe mainly bulbar MG) in the MG-0 group and from class 0
(pharmacological remission) to class 3B (moderate mainly bulbar MG)
in the MG + IMM group. Mean MGC score was 6.1 (range: 0 to 34) in
the MG-0 group and 4.6 (range: 0 to 18) in the MG + IMM group and
there was no difference in MGC scores between the groups (p = 0.2).
MGQ score was 40 ± 8 in the MG-0 group compared to 35 ± 10 in
theMG+ IMM group (p= 0.2). Antibody status is displayed in Table 1.
Taken together, patients were divided into two groups, based on
immunosuppression, that was quite homogenous regarding age
span although the individual clinical presentations were consider-
ably heterogeneous.
3.2. Circulating miR-150-5p and miR-21-5p are signiﬁcantly elevated in
sera from MG patients without immunosuppressive medication
We ﬁrst determined whether serum levels of circulating miR-150-
5p, miR-21-5p and miR-27a-3p would still be different in a heteroge-
neous group of MG patients without immunosuppression compared
to healthy controls and MG patients with immunosuppression.
Since hemolysis is a confounding parameter, one patient who had
a serum hemolysis quote of 7.9 in the MG + IMM group was exclud-
ed from further analysis. In the healthy control group, MG-0 and
MG + IMM, all reference genes had a stable expression pattern.
Since miR-93-5p was not expressed in the group of Addison's pa-
tients, only miR-103a, miR-423-3p and miR-191-5p were used for
normalization of miRNA expression data in the AID group.
As the primary objective, levels of miR-150-5p were signiﬁcantly
elevated with 170% in the MG-0 patients compared to the healthy
controls (p b 0.0001; Fig. 1A). Further, miR-150-5p levels were 41%
lower in the 36 MG + IMM patients compared to the MG-0 group
(p = 0.0051; Fig. 1A). For the subgroup of AChR+ patients, there
was an even more distinct difference with 55% lower values ofmiR-150-5p in the MG + IMM group (N = 26) compared to the
MG-0 group (N = 26; p = 0.003; Fig. 1B). Within the secondary ob-
jective, miR-21-5p was increased in MG-0 patients with 94% com-
pared to healthy controls (p b 0.0001). MG + IMM patients had 25%
lower miR-21-5p levels compared to MG-0 (p = 0.0419; Fig. 1C) and
in the subgroup of AChR+ patients MG + IMM patients had 16%
lower levels (data not shown). Levels of miR-27a-3p were not reduced
in the heterogeneous cohort ofMG-0 patients compared to healthy con-
trols (p = 0.33; Fig. 1D) and thus, not further analyzed.
BothmiR-150-5p andmiR-21-5pwere thus found to be elevated in a
large cohort ofMGpatientswithout immunosuppression and bothwere
signiﬁcantly reduced in patients with immunosuppression.
3.3. Circulating miR-150-5p and miR-21-5p are speciﬁcally elevated in MG
as compared to other autoimmune diseases
In order to determine whether levels of circulating miR-150-5p and
miR-21-5p would be disease speciﬁc for MG, sera were analyzed also
from the 23 patients with AIDs (Addison's disease, Crohn's disease and
psoriasis). In the AID group, mean levels of miR-150-5p were compara-
ble with those seen in the healthy controls (p = 0.66) and lower than
those in MG-0 patients (p = 0.0003; Fig. 1A). Also serum miR-21-5p
was not increased in patients with AID.
Both miR-150-5p and miR-21-5p were thus found to have a disease
speciﬁc elevation in MG patients without immunosuppression
3.4. No correlation between miR levels and clinical status
In theMG cohort, no correlationwas seen formiR-150-5p and age in
MG-0 (Spearman R=−0.184) and MG+ IMM (Spearman R= 0.094,
both p N 0.277). No difference was seen in miR-150-5p levels between
male and female patients (both MG-0 and MG+ IMM, p N 0.085). Fur-
ther, no clear relation was observed between the levels of miR-150-5p
and MG disease duration (MG-0 Spearman R = −0.134 and
MG + IMM Spearman R = 0.132; both p N 0.428). Disease severity
based on MGC score did not consistently correlate with miR-150-5p
levels in MG-0 (Spearman R = 0.119) and MG + IMM (Spearman
R = −0.095; both p N 0.482; Fig. 2). Correlation between MGQ and
miR-150-5p was consistent but weak for groups MG-0 (R = −0.07)
and MG-IMM (R =−0.15, both p N 0.69). There was no difference in
quality of life MGQ score between MG-0 and MG + IMM groups (p =
0.1640).
Within theMG-0 group, circulatingmiR-150-5p levels did not differ
between patients treated with AChEI and those who did not have any
current treatment (Fig. 3A). Further, we did not see any clear difference
between thymus histopathology, regarding normal thymus versus hy-
perplasia, andmiR-150-5p or antibody subgroup (data not shown). Ad-
ditionally, there was no clear association with MGFA disease severity
class and miR-150-5p levels (Fig. 3B).
For circulating miR-21-5p there was no correlation between levels
and MGC score (Spearman R = 0.076; p = 0.521).
Thus, although we found a disease speciﬁc signature of miR-21-5p
and miR-150-5p we were not able to signiﬁcantly correlate these levels
with any clinical parameters.
4. Discussion
Certain miRNAs are regarded as important modulators of immu-
nological functions. Both miR-150 and miR-21 are included among
these immuno-miRNAs, as they are considered to be crucial regula-
tors of T cell processes [20]. Since MG is a T cell dependent disease
it is intriguing that miR-150 has been identiﬁed as a miRNA selec-
tively expressed in immature, resting T cells with strong upregula-
tion as maturation/differentiation of T cells progresses [12,13]. We
recently proposed miR-150-5p as a potential circulating biomarker
in female AChR+ MG patients without immunosuppressive drug
Fig. 1. Box plots and individual values on linear axis of (A) miR-150-5p in the different cohorts. (B) Expression of miR-150-5p is displayed in the subgroups of AChR antibody seropositive
patients (AChR+) in theMG-0 and theMG+ IMMgroups respectively. (C) Box plots and individual values on linear axis ofmiR-21-5p and (D)miR-27a-3p in the different cohorts. To the
left in each cohort, individual values are displayed. Box plot with mean (horizontal line inside box), and whiskers (SD) are displayed to the right in each cohort. On the Y-axis, relative
expression of miR-150-5p and miR-21-5p are shown according to the formula 2^−ΔΔCT. HC, healthy controls (N = 55); MG-0, MG patients with no immunosuppressive treatment
(N= 34); MG + IMM, MG patients with immunosuppressive medication (N= 36) and AID (autoimmune disorders; N = 23). #p b 0.0001; **p b 0.01; *p b 0.05.
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improvement after thymectomy [10]. Nevertheless, a valid biological
parameter should preferably also be disease speciﬁc in a clinically
heterogeneous group of patients, both female and male as well as
early versus late onset MG. Therefore; in the present study we analyzed
miR-150-5p levels in a large cohort of MG patients with heterogeneous
clinical and serological phenotypes and with different treatments.Fig. 2. Relation plot of miR-150-5p and disease severity as measured by Myasthenia Gravis Com
150-5p and MGC score by MG cohort. MG-0 (circle), MG patients with no immunosuppressionIntriguingly, we found that the circulating miR-150-5p levels were
41% reduced in patients with current immunosuppressive drug treat-
ment, compared to patients without respective treatment.
Further, in the subgroup of AChR+ patients the difference was
more pronounced with 55% lower values in the immunosuppressed
group. Thymectomy was performed at a similar frequency in both
groups (approximately 50%) and thus there were no differenceposite Score (MGC) using linear regression. No consistent relation is seen regarding miR-
; MG+ IMM (triangle), MG patients with immunosuppression.
Fig. 3. A) Levels of miR-150-5p by treatment type. In the group of MG patients with immunosuppression (MG+ IMM), levels of miR-150-5pwere reduced by 41% compared to the group
of MG patients without immunosuppression (MG). AChEI, acetylcholinesterase inhibitors; aza, azathioprine; c, corticosteroids; c, aza, combination of corticosteroids and azathioprine; c,
myco; combination of corticosteroids andmycophenolate mofetil; c, send; combination of corticosteroids and sendoxan. B)miR-150-5p levels in relation to MGFA class of disease. MGFA
class 0, no myasthenic fatigue; MGFA class 1, ocular MG; MGFA class 2; mild generalized MG; MGFA class 3, moderate generalized MG; MGFA class 4, severe generalized MG.
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circulating miR-150-5p levels in MG patient sera respond to immuno-
modulatory treatments and not only to thymectomy. Nevertheless, we
cannot entirely rule out that other differences among patients in the
cohorts play a role, such as lower age at onset, and likely more early
onset MG patients, in the untreated group.
One questionwaswhether the levels ofmiR-150-5pwould correlate
with clinical score. We did not ﬁnd a consistent correlation between
miR-150-5p and the MGC score, however given the complexity of the
immune systemand the heterogeneity of the patients this is not entirely
surprising. The design of a cross-sectional cohort study might also be
less sensitive than a longitudinal study, which could detect subtle
changes within patients over time.
The other studied autoimmune disorders have a similar T cell me-
diated autoimmunity as MG. Addison's disease, Crohn's disease and
psoriasis share the T cell mediated pathophysiology although affect-
ing different organs. Psoriasis vulgaris is the best-understood disease
that is mediated by T cells and dendritic cells, with activation of IL-
17-producing T cells [21], similarly to the increase in IL-17 in Tregs
observed in MG [22]. Autoimmune adrenocortical failure, or
Addison's disease, is a prototypical organ-speciﬁc autoimmune dis-
order and Crohn's disease displays evidence of defects within the
Treg cell compartment [23]. Nevertheless, miR-150-5p levels were notfound to be altered in these other autoimmune disorders. The organ-
speciﬁc autoimmune disorders can be organized in two groups. The
ﬁrst group consists of autoimmune disorders in which the autoantigen
in a surface protein or receptor, such asMG or Grave's disease, associat-
edwith changes in thymic function. The other group consists of autoim-
mune disorders in which the autoantigen is an intra-cellular protein,
exempliﬁedwith Addison's disease. The ﬁrst group of autoimmune dis-
orders is not associated to thymomas or thymic changes. Accumulation
of miR-150-5p in MG patients, its reduction in patients with immuno-
suppressive drug treatment and its absence in destructive autoimmune
disorders may reﬂect the roles of miRNA-150-5p in the thymus and T
cell development.
Moreover, circulating miR-21-5p was elevated in a similar fash-
ion in MG patients compared to healthy controls and AID, although
the impact of immunosuppression was not as obvious as for miR-
150-5p. Previous reports have indicated importance of miR-21 in
lupus erythematosus, multiple sclerosis and diabetes type 1
[24–26] and thus it could be that certain types of AID share a
miRNA proﬁle and certain action of miR-21-5p in the immune cells.
Similar to miR-150, miR-21 plays crucial roles in T cells. Expression
of miR-21 is induced upon triggering of T cell receptors and affects
T cell activation through regulating T cell apoptosis, proliferation
and migration [27,28]. Further, the regulatory function of miR-21
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sistently higher expressed in Tregs, which is associated with the pre-
dominant memory phenotype of T cells [29].
The last miRNA that we assayed, miR-27a-3p, was not signiﬁcantly
reduced in this heterogeneous cohort of MG patients without immuno-
suppression and thus not assigned any disease speciﬁc value for further
studies in MG. This miRNA has been proposed to reﬂect natural killer
(NK) cell cytotoxicity [30] and it could be that this feature is not speciﬁc
enough for MG pathogenesis.
A relevant question is whether the treatment in the autoimmune
control group may have inﬂuenced the level of miR-150-5p. In gen-
eral, the absence of endogenous corticosteroids in patients with
Addison's disease is substituted with b30 mg hydrocortisone,
which is equivalent to 7.5 mg prednisone, and hence generally a
lower dose in comparison to the immunosuppression used in the
MG patients. The patients with psoriasis had only topical treatment
with corticosteroids and this treatment is not considered to give
rise to systemic immunosuppression. For the patients with Crohn's
disease, we were not able to obtain information about the immuno-
suppressive treatment at the time of serum sampling. However, con-
founding factors in control subjects may be subject for detailed
studies in future investigations.
The two different groups ofMG patients varied somewhat in the dis-
tribution of men and women, with more women in the MG-0 group.
However, the disease severity did not differ between the groups and
no sub-analysis was done for gender in this particular study. Additional-
ly, there is a sizeable cohort of antibody negative patients studied, more
than is generally reported in epidemiological studies, and this is due to
that most AChR seronegative patients are concentrated to Uppsala Uni-
versity Hospital. Further, we intentionally allowed the inclusion of a
proportionally large cohort of seronegative patients in order to broaden
the serological phenotype of the patients, since the initial study was
done on AChR+ patients alone [10].
A recent study analyzed the circulating miRNA proﬁle in MG pa-
tient sera and a number of miRNAs were decreased in MG patients
compared to healthy controls [31]. These down-regulated miRNAs
included miR-15b, miR-122, miR-140-3p, miR-185, miR-192, miR-
20b and miR-885-5p. The authors found the miRNA proﬁle to be
comparable between different subsets of MG with regard to early
onset MG, late onset MG and thymoma patients. There was also no
difference in patients with immunosuppressive drug treatment, tak-
ing into account that the number of patients in each subgroup was
rather small. Enhanced accumulation of circulating miRNAs was
not reported in the studied Spanish cohort; however it was not obvi-
ous which strand of mature miR-150 was analyzed. At present we do
not know the exact reasons for the discrepancy between the works
by Nogales-Gadea et al. [31] and our report. However, differences
in methods for detecting and normalizing circulating miRNAs
might explain the non-overlapping results.
In summary, circulating miR-150-5p and miR-21-5p speciﬁcally ac-
cumulate in sera from a heterogeneous group of MG patients. Primarily
the levels of circulatingmiR-150-5p are signiﬁcantly reduced inMG pa-
tients with immunosuppression, in particular AChR+ MG, indicating
responsiveness of miR-150-5p to immunomodulation. Therefore, dis-
ease speciﬁc signature of these circulating immuno-miRNAs in MG
might be considered as potential biological marker in future longitudi-
nal studies.
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